



US005166174A

United States Patent [19]

[11] Patent Number: **5,166,174**

Ueno et al.

[45] Date of Patent: **Nov. 24, 1992**

[54] **PROSTAGLANDINS E AND ANTI-ULCERS CONTAINING SAME**

[75] Inventors: **Ryuzo Ueno, Nishinomiya; Ryuji Ueno, Kyoto; Ichie Kato, Kawanishi; Tomio Oda, Itami, all of Japan**

[73] Assignee: **K.K. Ueno Seiyaku Oyo Kenkyujo, Osaka, Japan**

[21] Appl. No.: **700,895**

[22] Filed: **May 13, 1991**

Related U.S. Application Data

[63] Continuation of Ser. No. 406,830, Sep. 12, 1989, abandoned, which is a continuation-in-part of Ser. No. 149,445, Jan. 28, 1988, abandoned.

Foreign Application Priority Data

Jan. 28, 1987 [JP] Japan 62-18820
Mar. 18, 1987 [JP] Japan 62-65352

[51] Int. Cl.⁵ **C07C 177/00; A61K 31/557**

[52] U.S. Cl. **514/530; 514/573; 560/121; 502/503**

[58] Field of Search **560/121; 562/503; 514/530, 573**

[56] References Cited

U.S. PATENT DOCUMENTS

3,836,578 9/1974 Samuelsson 560/121
4,204,074 5/1980 Holland 562/503

OTHER PUBLICATIONS

Lee et al., "Effects of Oral Administration of PGE₂ . . . Ulcerations", Prostaglandins, Jan. 1973 vol. 3, No. 1, pp. 29-45.

Anggard, "The Biological Activities of Three Metabolites of Prostaglandin E₁", Acta physiol. scand. 1966, 66, pp. 509-510.

Primary Examiner—Robert Gerstl
Attorney, Agent, or Firm—Sughrue, Mion, Zinn, Macpeak & Seas

[57] ABSTRACT

The novel 13,14-dihydro-15-keto prostaglandins E of the invention have remarkable preventive effects against ulcers. Further, the novel 13,14-dihydro-15-keto-prostaglandins E of the invention have an advantage that they have none of side effects which prostaglandin E intrinsically has, or can remarkably reduce such effects of the prostaglandin E. Therefore, the novel 13,14-dihydro-15-keto prostaglandins E of the invention are effective for animal and human use for treatment and prevention of ulcers, such as duodenal ulcer and gastric ulcer.

38 Claims, 57 Drawing Sheets